Predicted candidate drugs for each prognostic group according to CMap
| Drug class | Cultured cell lines tested (n) | Mean normalized connectivity scores (95% CI) | P value* | Prognostic group candidate for this drug class |
| Adrenergic receptor agonist | 82 | 0.40 (0.16 to 0.63) | 1.11E−03 | Good-prognosis group |
| Acetylcholine receptor antagonist | 75 | 0.31 (0.06 to 0.56) | 1.70E−02 | Good-prognosis group |
| Dopamine receptor antagonist | 203 | −0.24 (−0.40 to 0.08) | 3.61E−03 | Poor-prognosis group |
| DNA inhibitor | 103 | −0.31 (−0.55 to 0.07) | 1.12E−02 | Poor-prognosis group |
| Retinoid receptor agonist | 76 | −0.35 (−0.62 to 0.08) | 1.26E−02 | Poor-prognosis group |
| Bcr-Abl inhibitor | 92 | −0.37 (−0.62 to 0.11) | 5.53E−03 | Poor-prognosis group |
| Aurora kinase inhibitor | 90 | −0.42 (−0.69 to 0.15) | 2.65E−03 | Poor-prognosis group |
| Calcium channel blocker | 104 | −0.42 (−0.64 to 0.21) | 1.99E−04 | Poor-prognosis group |
| Abl inhibitor | 108 | −0.49 (−0.72 to 0.26) | 5.11E−05 | Poor-prognosis group |
| NFKB inhibitor | 72 | −0.52 (−0.76 to 0.27) | 7.51E−05 | Poor-prognosis group |
| JAK inhibitor | 79 | −0.52 (−0.79 to 0.24) | 3.35E−04 | Poor-prognosis group |
| Glucocorticoid receptor agonist | 102 | −0.53 (−0.73 to 0.33) | 1.11E−06 | Poor-prognosis group |
| FLT3 inhibitor | 103 | −0.56 (−0.80 to 0.32) | 8.98E−06 | Poor-prognosis group |
| PDGFR inhibitor | 134 | −0.58 (−0.78 to 0.39) | 1.26E−08 | Poor-prognosis group |
| KIT inhibitor | 96 | −0.63 (−0.87 to 0.39) | 7.22E−07 | Poor-prognosis group |
| Src inhibitor | 76 | −0.65 (−0.91 to 0.39) | 4.28E−06 | Poor-prognosis group |
| RAF inhibitor | 58 | −0.65 (−0.95 to 0.35) | 6.01E−05 | Poor-prognosis group |
| MEK inhibitor | 88 | −0.66 (−0.91 to 0.41) | 1.14E−06 | Poor-prognosis group |
| PI3K inhibitor | 182 | −0.67 (−0.84 to 0.50) | 7.61E−13 | Poor-prognosis group |
| IKK inhibitor | 55 | −0.67 (−0.97 to 0.36) | 4.96E−05 | Poor-prognosis group |
| Tyrosine kinase inhibitor | 63 | −0.70 (−0.97 to 0.42) | 3.59E−06 | Poor-prognosis group |
| ATPase inhibitor | 81 | −0.71 (−0.93 to 0.50) | 2.41E−09 | Poor-prognosis group |
| VEGFR inhibitor | 196 | −0.73 (−0.88 to 0.58) | 3.05E−18 | Poor-prognosis group |
| EGFR inhibitor | 381 | −0.77 (−0.87 to 0.66) | 1.15E−37 | Poor-prognosis group |
| FGFR inhibitor | 58 | −0.77 (−1.04 to 0.50) | 4.86E−07 | Poor-prognosis group |
| MTOR inhibitor | 131 | −0.81 (−1.00 to 0.63) | 1.37E−14 | Poor-prognosis group |
| Topoisomerase inhibitor | 136 | −0.89 (−1.06 to 0.72) | 7.29E−19 | Poor-prognosis group |
| AKT inhibitor | 60 | −0.99 (−1.20 to 0.78) | 1.84E−13 | Poor-prognosis group |
| CDK inhibitor | 129 | −1.09 (−1.24 to 0.94) | 5.76E−28 | Poor-prognosis group |
| HDAC inhibitor | 148 | −1.19 (−1.27 to 1.11) | 5.63E−62 | Poor-prognosis group |
*One sample Student’s t-test.
AKT, protein kinase B; CDK, cyclin-dependant kinase; EGFR, epidermal growth factor receptor; HDAC, histone deacetylase; MTOR, mechanistic target of rapamycin kinase; VEGFR, vascular endothelial growth factor receptor.